Mika Chiba

5.1k total citations
8 papers, 241 citations indexed

About

Mika Chiba is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Mika Chiba has authored 8 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 3 papers in Surgery and 3 papers in Oncology. Recurrent topics in Mika Chiba's work include Lung Cancer Treatments and Mutations (5 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). Mika Chiba is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). Mika Chiba collaborates with scholars based in Japan and United States. Mika Chiba's co-authors include Akihiko Gemma, Masahiro Seike, Kaoru Kubota, Rintaro Noro, Masaru Matsumoto, Akihiko Miyanaga, Shinji Nakamichi, Nobuhiko Nishijima, Teppei Sugano and Chie Soeno and has published in prestigious journals such as Gut, Scientific Reports and Oncotarget.

In The Last Decade

Mika Chiba

8 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mika Chiba Japan	7	139	120	95	75	31	8	241
Jianjun Xiao China	9	89 0.6×	115 1.0×	72 0.8×	75 1.0×	30 1.0×	16	222
Melinda Garcia United States	4	166 1.2×	55 0.5×	94 1.0×	86 1.1×	22 0.7×	5	239
Biao He United States	10	172 1.2×	106 0.9×	188 2.0×	78 1.0×	18 0.6×	13	370
Marta Román Spain	5	168 1.2×	116 1.0×	126 1.3×	68 0.9×	23 0.7×	7	306
Wenzhuan Xie China	8	97 0.7×	114 0.9×	109 1.1×	98 1.3×	27 0.9×	18	238
Huita Wu China	7	189 1.4×	72 0.6×	79 0.8×	93 1.2×	22 0.7×	15	273
Genhao Zhang China	9	147 1.1×	64 0.5×	141 1.5×	144 1.9×	47 1.5×	19	273
María Ochoa-de-Olza Spain	5	117 0.8×	116 1.0×	50 0.5×	73 1.0×	62 2.0×	7	243
Anna Bellmunt Spain	3	106 0.8×	135 1.1×	43 0.5×	72 1.0×	26 0.8×	4	229
Shi‐Xun Lu China	12	109 0.8×	120 1.0×	96 1.0×	64 0.9×	24 0.8×	21	277

Countries citing papers authored by Mika Chiba

Since Specialization

Citations

This map shows the geographic impact of Mika Chiba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika Chiba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika Chiba more than expected).

Fields of papers citing papers by Mika Chiba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika Chiba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika Chiba. The network helps show where Mika Chiba may publish in the future.

Co-authorship network of co-authors of Mika Chiba

This figure shows the co-authorship network connecting the top 25 collaborators of Mika Chiba. A scholar is included among the top collaborators of Mika Chiba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika Chiba. Mika Chiba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Kobayashi, Kenichi, Masahiro Seike, Rintaro Noro, et al.. (2018). Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression. Anticancer Research. 38(2). 753–762. 18 indexed citations

2.

Takahashi, Akiko, Masahiro Seike, Mika Chiba, et al.. (2018). Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. Scientific Reports. 8(1). 14896–14896. 43 indexed citations

3.

Nakamichi, Shinji, Masahiro Seike, Akihiko Miyanaga, et al.. (2018). Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. Oncotarget. 9(43). 27242–27255. 32 indexed citations

4.

Nakamichi, Shinji, Masahiro Seike, Akihiko Miyanaga, et al.. (2017). RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients. Anticancer Research. 37(6). 3295–3299. 8 indexed citations

5.

Seike, Masahiro, Cheol-Hong Kim, Rintaro Noro, et al.. (2017). AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncology Reports. 37(6). 3261–3269. 16 indexed citations

6.

Nishijima, Nobuhiko, Masahiro Seike, Chie Soeno, et al.. (2016). miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. International Journal of Oncology. 48(3). 937–944. 61 indexed citations

7.

Sugano, Teppei, Masahiro Seike, Rintaro Noro, et al.. (2015). Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 14(11). 2433–2440. 57 indexed citations

8.

Chiba, Mika, Leroy C. McLaren, & R. G. Strickland. (1982). Immunity to cytopathic agents associated with Crohn's disease: a negative study.. Gut. 23(4). 333–339. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact